214 related articles for article (PubMed ID: 22466256)
1. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
2. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
4. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
5. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa.
Zaher M; Tang R; Bombarda I; Merhi F; Bauvois B; Billard C
Int J Oncol; 2012 Jan; 40(1):269-76. PubMed ID: 21947285
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
[TBL] [Abstract][Full Text] [Related]
8. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
9. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
11. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
12. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
[TBL] [Abstract][Full Text] [Related]
13. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
15. Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia.
Besbes S; Mirshahi M; Pocard M; Billard C
Blood Rev; 2015 Sep; 29(5):345-50. PubMed ID: 25887155
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
17. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
19. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
20. Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance.
Iglesias-Serret D; Piqué M; Barragán M; Cosialls AM; Santidrián AF; González-Gironès DM; Coll-Mulet L; de Frias M; Pons G; Gil J
Apoptosis; 2010 Feb; 15(2):219-29. PubMed ID: 19936928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
